Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Sweden

Research and Innovation Action · Running

CCHFVACIM Crimean-Congo Haemorrhagic Fever Vaccine and Immunotherapy

Coordinator
Folkhalsomyndigheten, Sweden
Runs
1 January 2024 to 31 December 2027
Status
Running
EU funding
€7.8m
Total cost
€7.8m
Partners
15 organisations in 10 countries
Type
Research and Innovation Action
Grant agreement
101137033

What the project is doing

In the project's own words, from its summary on CORDIS.

The CCHFVACIM project is an ambitious collaborative effort aimed at developing both prophylactic and therapeutic effective countermeasures against Crimean Congo Haemorrhagic Fever Virus (CCHFV), one of the most threatening vector-borne pathogens, widely distributed, including in the European continent. Deep structural biology studies on viral glycoproteins and investigation of the immunogenicity of the viral antigens will be combined with optimisation of an mRNA vaccine candidate against the virus and characterisation of the resulting protective immunity, as well as with the development of immunotherapeutic monoclonal antibodies (mAbs) based on CCHFV’s antigenic targets.

To achieve the overarching goals, the CCHFVACIM project will build on the success of previous projects such as CCHFever (FP7), CCHFVaccine (H2020) and go the extra mile by initiating a unique One-Health platform strategy to address different aspects of this severe public health threat. On one hand, the project will use several advanced animal models (mice, sheep, and non-human primate) to assess and compare the efficacy of mRNA vaccine candidates, mAbs and therapeutic mRNA; on the other hand, it will establish a biobank from CCHF patients to build up a pipeline for the production of mAbs against CCHFV from their B cells.

Importantly, the project will also contribute to capacity building of European infrastructures, with the establishment of a platform on mRNA-based vaccine at one of the partner institutions. Ultimately, CCHFVACIM will permit to develop a road map to bring the most efficacious vaccine candidates and immunotherapy tools to clinical trial Phase I in humans. The project results will be widely disseminated among the scientific community, public health authorities, non-governmental organisations, outbreak management teams, and hospitals, with the final scope of both contributing to contain the burden of CCHF disease and increasing preparedness to new outbreaks.

Topics

Who is involved

OrganisationCityCountryRole
FolkhalsomyndighetenSolnaSwedenCoordinator
European Research Infrastructure on Highly Pathogenic AgentsBruxelles / BrusselBelgiumParticipant
National Center of Infectious and Parasitic Diseases NcipdSofiaBulgariaParticipant
Friedrich Loeffler Institut - Bundesforschungsinstitut Fuer TiergesundheitGreifswald-Insel RiemsGermanyParticipant
Justus-Liebig-Universitaet GiessenGiessenGermanyParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceThird party
Institut PasteurParisFranceParticipant
Institut Pasteur Du CambodgePhnom PenhKHParticipant
International Vaccine InstituteSeoulSouth KoreaParticipant
Karolinska InstitutetStockholmSwedenParticipant
Statens Veterinaermedicinska AnstaltUppsalaSwedenParticipant
Sivas Cumhuriyet UniversitesiSivasTürkiyeParticipant
Department of HealthLeedsUnited KingdomAssociatedpartner
The Trustees of the University of Pennsylvania CorpPhiladelphiaUnited StatesParticipant
United States Department of Health and Human ServicesWashington D.C.United StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI